Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation
- PMID: 2594781
- PMCID: PMC298521
- DOI: 10.1073/pnas.86.23.9485
Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation
Abstract
The interleukin 2-diphtheria toxin-related fusion protein (IL-2-toxin) rapidly inhibits protein synthesis in IL-2 receptor (IL-2R)-bearing phytohemagglutinin-activated T cells but transiently stimulates DNA synthesis. At 7 hr after interaction with IL-2R+ phytohemagglutinin-activated T cells, IL-2-toxin-treated cells bear augmented steady-state levels of c-myc, interferon gamma, and IL-2R mRNA; these effects are indistinguishable from those produced by recombinant IL-2. Amplification of IL-2 sequences by the polymerase chain reaction reveals an increased level of IL-2 mRNA in cell cultures treated with recombinant IL-2, IL-2-toxin, and cycloheximide. These results suggest that IL-2-toxin can affect de novo IL-2 gene transcription/mRNA stabilization through independent mechanisms exerted by both the IL-2R binding domain and ADP-ribosyltransferase activity of the fusion protein. After 20 hr of culture, IL-2R mRNA was markedly decreased in both IL-2-toxin- and cycloheximide-treated phytohemagglutinin-activated T cells. Although interaction of IL-2-toxin with IL-2R+ T cells initially mimics the stimulatory effects of IL-2 upon c-myc, interferon gamma, IL-2R, and IL-2 gene expression, the consequences of inhibition of protein synthesis mediated by the ADP-ribosyltransferase activity of the toxin dominate after 7 hr and are indistinguishable from those effects mediated by cycloheximide.
Similar articles
-
A kinetic analysis of the effects of interleukin-2 diphtheria toxin fusion protein upon activated T cells.Transplantation. 1990 Jan;49(1):198-201. doi: 10.1097/00007890-199001000-00044. Transplantation. 1990. PMID: 2301012
-
Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.Dig Dis Sci. 1997 Jul;42(7):1542-8. doi: 10.1023/a:1018891432581. Dig Dis Sci. 1997. PMID: 9246061
-
Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia.Cancer Res. 1989 Jul 15;49(14):4042-6. Cancer Res. 1989. PMID: 2786749
-
Genetic assembly and selective toxicity of diphtheria-toxin-related polypeptide hormone fusion proteins.Biochem Soc Symp. 1987;53:9-23. Biochem Soc Symp. 1987. PMID: 2847744 Review.
-
DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology.Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31. Clin Lymphoma. 2000. PMID: 11707860 Review.
Cited by
-
Bacteria-derived chimeric toxins as potential anticancer agents.Front Oncol. 2022 Sep 7;12:953678. doi: 10.3389/fonc.2022.953678. eCollection 2022. Front Oncol. 2022. PMID: 36158673 Free PMC article. Review.
-
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7866-71. doi: 10.1073/pnas.122157899. Proc Natl Acad Sci U S A. 2002. PMID: 12060733 Free PMC article.
-
Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.J Immunother. 2008 Feb-Mar;31(2):189-98. doi: 10.1097/CJI.0b013e31815dc0e8. J Immunother. 2008. PMID: 18481388 Free PMC article. Clinical Trial.
-
Anti-leukemia activity of a bacterial toxin with natural specificity for LFA-1 on white blood cells.Leuk Res. 2010 Jun;34(6):777-85. doi: 10.1016/j.leukres.2009.08.022. Epub 2009 Sep 10. Leuk Res. 2010. PMID: 19747730 Free PMC article.
-
Leukotoxin kills rodent WBC by targeting leukocyte function associated antigen 1.Comp Med. 2013 Aug;63(4):331-7. Comp Med. 2013. PMID: 24209968 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources